EVONasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as EVOTF
Evotec SE
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 8, 2026
$1.42+0.04 (+2.90%)
Close on Oct 19, 2026
Evotec SE cash flow statement
Ratios
Latest available, balances at Dec 31, 2025
Profitability, FY2025
- Gross margin
- 14.5%
- Operating margin
- -7.1%
- Net margin
- –
- Return on equity, FY2025
- –
Financial strength
- Current ratio
- 2.07
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 113.7%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
Valuation ratios need the share price and fill in once daily prices are connected.